Affiliation:
1. Ryzhikh National Medical Research Center of Coloproctology
2. Ryzhikh National Medical Research Center of Coloproctology; Russian Medical Academy of Continuous Professional Education
Abstract
AIM: to improve the results of chronic anal fissure treatment. PATIENTS AND METHODS: the study included 22 patients randomized by random numbers generation method into 2 groups. Eleven patients were included in main group and were treated with 0.3 % nifedipine + 2.0 % lidocaine gel, 11 patients of the control group received injections of botulinum toxin A into the internal anal sphincter at a dose of 80 U (BTA 80). RESULTS: by day 30, there was a decrease of maximal resting pressure in anal canal (MRPAC) in both the main and control groups [p = 0.015 and p = 0.004, respectively] and the average resting pressure in anal canal (ARPAC) [p = 0.01 and p = 0.02, respectively]. There was no difference between the groups in pain severity both after stool and during the day (p = 0.5 and p = 0.6, respectively). On day 60, the defect was epithelized in 6/11 (54.6 %) patients of the study group and in 9/11 (81.8 %) patients of the BTA 80 group [p = 0.36], respectively. The reason of treatment failure in 4/11 (36.4 %) patients of the main group and 2/11 (18.2 %) patients of the control group was a preserved internal sphincter spasm. It was found that these patients used a lower amount of the drug product — 2.2 (1.8; 2.5) mg/day compared to 2.4 (1.9; 2.7) mg/day in other patients. On the day 30 after surgical treatment, complaints about gas incontinence were registered in 1/11 (9.1 %) patients of the main group and 1/11 (9.1 %) patients of the control group [p = 1]. Such a complication as external hemorrhoid thrombosis occurred only in 1/11 (9.1 %) patients in the BTA 80 group [p = 0.87]. CONCLUSION: the study results show that gel containing 0.3 % nifedipine and 2 % lidocaine produces an effect on the tone of the internal sphincter comparable to BTA. However, the lack of accurate dosage of the drug product and/or low patient compliance reduce the effectiveness of treatment and make the use of BTA preferable for medical relaxation of the internal sphincter.
Publisher
Russian Association of Coloproctology
Reference11 articles.
1. Veselov A.V. Analysis of medical statistics on the provision of coloproctological care to the population of Moscow. Klinicheskij opyt Dvadcatki. 2014;24(4):26–29. (In Russ).
2. Zharkov E.E. Complex treatment of chronic anal fissure. Abstract diss. cand. med. sciences. 2009; М., 113 p. (in Russ.).
3. Shelygin Yu.A., Podmarenkova L.F., Zharkov E.E. et al. Possibilities of drug relaxation of the internal sphincter in patients with chronic anal fissure. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2005;15(1):87–92. (in Russ.) doi: 10.21518/1995-1477-2021-18-2-105-110
4. Agapov M.A., Aliev F.Sh., Achkasov S.I. et al. Clinical guidelines. Anal fissure. Koloproctologia. 2021;20(4):10–21. (in Russ.). doi: 10.33878/2073-7556-2021-20-4-10-21
5. Khryukin R.Yu., Kostarev I.V., Arslanbekova K.I., et al. Botulinum toxin type A and lateral subcutaneous sphincterotomy for chronic anal fissure with the sphincter spasm. What to choose? (systematic literature review and meta-analysis). Koloproktologia. 2020;19(2):113–128. (in Russ.). doi: 10.33878/2073-7556-2020-19-2-113-128